Warfarin is a vitamin K antagonist that genetic and non-genetic factors affected on its doserequirement in the patients with cardio vascular disease. The aim of this study was whetherthe APOE and VKORC1 polymorphisms influence on warfarin dose requirements in the partof Iranian patients. Blood samples were collected from 86 warfarin-treated patients. Afterextraction of genomic DNA, the VKORC1 (...

normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background : many patients using warfarin may be at risk of international normalized ratio fluctuations. this may cause severe massive gastrointestinal or cerebral bleeding. subclinical hypothyroidism in our population is highly prevalent (range from 3.1% to 8.4% for males and females respectively). overt hypothyroidism di...

Previous studies have shown that patients with anticoagulation (warfarin)-associated intracerebral hemorrhage (WAICH) have poor outcome and greater mortality. The mechanisms by which warfarin worsens intracerebral hemorrhage (ICH) outcome are not clearly defined and include larger hematoma volumes at presentation, ongoing bleeding leading to greater hematoma expansion, and greater age and burde...

STUDY OBJECTIVE The acute management of patients on warfarin with spontaneous or traumatic intracranial hemorrhage continues to be debated in the medical literature. The objective of this paper was to conduct a structured review of the medical literature and summarize the advantages and risks of the available treatment options for reversing warfarin anticoagulation in patients who present to th...

Despite these advantages, clinicians have been concerned over the lack of specific reversal agents for use in the event of a life-threatening bleeding event or when an emergent interventional procedure is required. This concern may limit the use of DOACs, as warfarin can be reversed with the combination of a factor product (fresh frozen plasma or prothrombin complex concentrate) and phytonadion...

Non-vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin for stroke prevention in atrial fibrillation and management of venous thromboembolism. In clinical practice, there is still widespread uncertainty on how to manage patients on NOACs who bleed or who are at risk for bleeding. Clinical trial data related to NOAC reversal for bleeding and perioperative manage...

warfarin induced skin necrosis is a rare complication associated with the use of oral ‎anticoagulants. most patients develop this complication at the initiation of therapy. the complication is ‎usually associated with an underlying thrombophilia. here we describe a case of a 75 year old ‎patient who developed skin necrosis in her both breasts during warfarin treatment for a ‎deep vein thrombosi...

Dabigatran is a direct thrombin inhibitor recently approved in the United States and Canada for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Although dabigatran is administered as a fixed dose, does not interact with foods, and has fewer drug interactions than warfarin, the risk of hemorrhagic complications is similar for these two drugs. There is no specif...